SCHEMBL2011079

SCHEMBL2011079

Cc1c(OCC(=O)OCc2ccccc2)ccc(C(=O)CN2Cc3cc(C#N)ccc3C2=O)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PTGDR2 Q9Y5Y4 3/20 0.35
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
GRM2 Q14416 1/20 0.34
SLC6A9 P48067 1/20 0.34
NPC1 O15118 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013747 0.90 GABRA1 (0.39) L3MBTL1SMN1; SMN2MAPTPRMT5WDR77
SCHEMBL2010825 0.90 PRMT5 (0.34) L3MBTL1MAPTCYP2C9PTGDR2ITGB3
SCHEMBL2008007 0.86 ITGB3 (0.42) L3MBTL1MAPTITGB3ITGA2BPRMT5
SCHEMBL2008157 0.85 ITGB3 (0.41) L3MBTL1SMN1; SMN2MAPTCYP2C9CYP2C19
SCHEMBL2009384 0.84 ITGB3 (0.40) L3MBTL1SMN1; SMN2MAPTCYP2C9CYP2C19
SCHEMBL2053007 0.83 GABRA1 (0.38) L3MBTL1PTGDR2PRMT5WDR77ALOX15
SCHEMBL2008864 0.83 GABRA1 (0.38) L3MBTL1MAPTPTGDR2PRMT5WDR77
SCHEMBL2014061 0.83 GABRA1 (0.38) L3MBTL1SMN1; SMN2PRMT5WDR77NPC1
SCHEMBL2011666 0.82 ITGB3 (0.46) L3MBTL1SMN1; SMN2MAPTITGB3ITGA2B
SCHEMBL2007123 0.81 GABRA1 (0.37) MAPTCYP2C9TDP1PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 L3MBTL1 4640/4885SMN1; SMN2 4690/4885MAPT 4727/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 L3MBTL1 4640/4885SMN1; SMN2 4690/4885MAPT 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.